FDA approves new pill for advanced breast cancer guided by blood test
The U.S. Food and Drug Administration (FDA) has approved a new daily pill for adults with advanced breast cancer whose tumors have found a way around their current treatment.
The Trump administration has permanently appointed four new leaders at the Food and Drug Administration (FDA), following the nomination of Heidi Overton to serve as the agency's director. Three of the officials are taking their roles in an acting capacity, which will officially become permanent. Michael Davis, a psychiatrist, will lead the Center for Drug Evaluation and Research.
Karim Mikhail, formerly of Merck, will head the Center for Biologics Evaluation and Research. Bret Koplow, an attorney with FDA experience since 2011, will direct the Center for Tobacco Products. Additionally, Jared Seehafer has been appointed as the FDA's first deputy commissioner for technology and artificial intelligence. Seehafer joined the agency as an adviser in 2025 after founding a life science software company and working in investment advising for biotech. The FDA has been utilizing AI to streamline its review processes under the Trump administration.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
